Forte Biosciences Inc
NASDAQ:FBRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Dreamfolks Services Ltd
NSE:DREAMFOLKS
|
IN |
|
Balrampur Chini Mills Ltd
NSE:BALRAMCHIN
|
IN |
|
Jiangsu Huaxin New Material Co Ltd
SZSE:300717
|
CN |
Forte Biosciences Inc
Cash from Operating Activities
Forte Biosciences Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Forte Biosciences Inc
NASDAQ:FBRX
|
Cash from Operating Activities
-$50.9m
|
CAGR 3-Years
-84%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-9%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$19B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$10B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$10B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.6B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
14%
|
CAGR 10-Years
14%
|
|
Forte Biosciences Inc
Glance View
Forte Biosciences, Inc. is a clinical stage biopharmaceutical company focused on dermatology. The company is headquartered in Torrance, California and currently employs 5 full-time employees. The company went IPO on 2017-04-13. The firm is focused on its lead product candidate, FB-401, which is a topical live biotherapeutic for the treatment of inflammatory skin diseases, including pediatric and adult patients with atopic dermatitis (AD). FB401 was developed in collaboration with the National Institutes of Health (NIH), and the National Institute of Allergy and Infectious Diseases (NIAID). FB-401 has completed Phase I/II a testing in adult and pediatric patients with atopic dermatitis.
See Also
What is Forte Biosciences Inc's Cash from Operating Activities?
Cash from Operating Activities
-50.9m
USD
Based on the financial report for Dec 31, 2025, Forte Biosciences Inc's Cash from Operating Activities amounts to -50.9m USD.
What is Forte Biosciences Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-9%
Over the last year, the Cash from Operating Activities growth was -65%. The average annual Cash from Operating Activities growth rates for Forte Biosciences Inc have been -84% over the past three years , -23% over the past five years , and -9% over the past ten years .
